The concept stock of antidiarrheal drug "montmorillonite scatter" strengthened, and Kangzhi Pharmaceutical and Tongyuan Pharmaceutical "20CM" rose to the limit

【Pharmaceutical Network Pharmaceutical Stock Market】Affected by the epidemic, antidiarrheal drugs montmorillonite are out of stock
.
The concept of montmorillonite scatter in the capital market has attracted attention, among which Kangzhi Pharmaceutical and Tongyuan Pharmaceutical have risen by nearly 20%, in addition, Fangsheng Pharmaceutical, Yiming Pharmaceutical and other stocks have increased their limits
.
China Resources Shuanghe, Jincheng Pharmaceutical, Zhongguancun and so on followed
.
Kangzhi Pharmaceutical opened "20CM" on January 3 to increase the limit, reported 7.
46 yuan, and currently sealed 14461 lots, equivalent to 10.
7879 million yuan
.
Up to now, the transaction has been 58.
7415 million yuan, with a turnover rate of 1.
81%.

Kangzhi Pharmaceutical responded to investors on the interactive platform on January 3 that the company produces and sells montmorillonite, and the product has passed the quality and efficacy consistency evaluation
of generic drugs in early 2021.
At present, the company works overtime production through external recruitment, transfer of employees from other bases, adjustment of shifts, etc.
, to ensure the supply of
products.
In addition, a relevant person from the investor relations department of Kangzhi Pharmaceutical said that for the proportion of montmorillonite retail revenue, the (drug) classification is only children's drugs and adult drugs, but it is not divided into individual products
.
In terms of orders, the person said that after the optimization of epidemic prevention, the overall (order) volume of montmorillonite powder, ibuprofen, cold clear heat granules, cough orange red granules and other products is very large, we are all working overtime, working several shifts at night, and New Year's Day is not on holiday in order to rush work
.
On January 3, Tongyuan Pharmaceutical opened at 7.
68 yuan, and as of 09:43, the stock rose 19.
94% to 8.
12 yuan, closing the rise
.
The company is mainly engaged in the research and development, production, sales of medicine and health food, medical diagnosis, gene preservation, pregnancy environment testing and other medical and health services and commercial business
.
On the news, Tongyuan Pharmaceutical said that the company's products have montmorillonite powder, and the company's products montmorillonite powder passed the consistency evaluation
.
At 9:26 on January 3, Fangsheng Pharmaceutical opened at 8.
81 yuan, and the current closed orders 789875 hands, equivalent to 696 million yuan
.
Up to now, the transaction has been 9.
5562 million yuan, with a turnover rate of 0.
25%.

Fangsheng Pharmaceutical is mainly engaged in the research and development, production and sales of cardiovascular and cerebrovascular proprietary Chinese medicines, orthopedic drugs, pediatric drugs, gynecological drugs, anti-infective drugs and other drugs
.
The main products are blood plug dispersible tablets, blood plug tablets, Garcinia cambogia bone tablets, lysine vitamin B12 granules, cefixime tablets, Jinying capsules, etc
.
Fangsheng Pharmaceutical is also classified as the concept of montmorillonite scatter, because it had interacted with Yiyi on June 1, 2021: the pediatric disease drugs that the company has been approved for production and sale mainly include: pediatric Jingxing cough granules, pediatric compound tetravia iron powder, lysine vitamin B12 granules, and montmorillonite powder
.
According to Fangsheng Pharmaceutical's 2021 annual report, in January 2021, the company received the "Drug Supplement Application Approval Notice" issued by the State Food and Drug Administration on montmorillonite powder, confirming that the drug passed the consistency evaluation of the quality and efficacy of generic drugs, and the company sold 54.
9048 million bags
of montmorillonite powder that year.
At 9:26 on January 3, Yiming Pharmaceutical opened at 11.
21 yuan, and the current closed order is 140869 lots, equivalent to 158 million yuan
.
Up to now, the transaction has been 4.
206 million yuan, with a turnover rate of 0.
21%.

According to the data, Yiming Pharmaceutical is mainly engaged in the research and development, production and sales
of chemical drugs (APIs and preparations) and proprietary Chinese medicines.
The main drugs produced and sold by the company are divided into treatment areas and characteristics, which can be classified as diabetes drugs, coronary heart disease drugs, opioid receptor antagonist drugs, breast hyperplasia disease drugs, anti-inflammatory and anti-rheumatic drugs
.
According to the 2022 annual report of Yiming Pharmaceutical: the company has montmorillonite powder (Beiyipin) suitable for acute and chronic diarrhea in adults and children, and passed the consistency evaluation
in June 2018.
The montmorillonite API and preparation production line project obtained the EIA report and EIA approval documents in 2019, and passed the independent acceptance test report in December 2020 and obtained the independent acceptance test report
after the expert on-site review.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.